Bortezomib prevents cytarabine resistance in MCL, which is...

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Freiburghaus, Catja, Emruli, Venera Kuci, Johansson, Angelica, Eskelund, Christian Winther, Grønbæk, Kirsten, Olsson, Roger, Ek, Fredrik, Jerkeman, Mats, Ek, Sara
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
18
Language:
english
Journal:
BMC Cancer
DOI:
10.1186/s12885-018-4346-1
Date:
December, 2018
File:
PDF, 5.02 MB
english, 2018
Conversion to is in progress
Conversion to is failed